ESC 2019 Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduced ischemic endpoints as compared with ticagrelor, without an increased bleeding risk.
ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.
ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.
ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidaemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.
ESC 2019 The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.
ESC 2019 Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.
ESC 2019 The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.
ESC 2019 The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.
ESC 2019 The PURE study shows that in high-income countries, cancer accounts for more deaths than CVD, while in low-income countries CVD mortality is higher, although risk factors are lower there.
ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.